{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hwang JP"],"funding":["NCI NIH HHS"],"pagination":["959-967"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7351320"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(10)"],"pubmed_abstract":["Purpose
Most patients with cancer are not screened for hepatitis B virus (HBV) infection before undergoing anticancer therapy, and optimal screening strategies are unknown. We sought to develop selective HBV screening strategies for patients who require systemic anticancer therapy.Methods
This prospective cohort study included adults age ≥ 18 years with solid or hematologic malignancies who received systemic anticancer therapy at a comprehensive cancer center during 2013 and 2014. Patients underwent hepatitis B surface antigen, hepatitis B core antibody, and hepatitis B surface antibody testing, and completed a 19-question modified Centers for Disease Control and Prevention (CDC) HBV survey. Multivariable models that predict chronic or past HBV infection were developed and "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study."],"pmcid":["PMC7351320"],"funding_grant_id":["K07 CA132955"],"pubmed_authors":["Granwehr BP","Cantor SB","Ahmed S","Romaguera J","Hwang JP","Fisch MJ","Vierling JM","Lin HY","Foreman JT","Simon GR","Ferrajoli A","Suarez-Almazor ME","Lok AS","Barbo A","Torres HA","Miller E","Eng C"],"additional_accession":[]},"is_claimable":false,"name":"Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.","description":"Purpose
Most patients with cancer are not screened for hepatitis B virus (HBV) infection before undergoing anticancer therapy, and optimal screening strategies are unknown. We sought to develop selective HBV screening strategies for patients who require systemic anticancer therapy.Methods
This prospective cohort study included adults age ≥ 18 years with solid or hematologic malignancies who received systemic anticancer therapy at a comprehensive cancer center during 2013 and 2014. Patients underwent hepatitis B surface antigen, hepatitis B core antibody, and hepatitis B surface antibody testing, and completed a 19-question modified Centers for Disease Control and Prevention (CDC) HBV survey. Multivariable models that predict chronic or past HBV infection were developed and ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2025-06-01T02:34:52.353Z","creation":"2020-11-19T13:29:05Z"},"accession":"S-EPMC7351320","cross_references":{"pubmed":["29447061"],"doi":["10.1200/JCO.2017.75.6387","10.1200/jco.2017.75.6387"]}}